Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

F4/4BIO Capital/Activity

4BIO Capital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio company Trogenix dosed its first patient in a Phase I/II trial (ADePT) of TGX-007, a dual-payload AAV gene therapy for glioblastoma.

Trogenix

Trogenix 4BIO Capital

4biocapital.comJUN 25, 2026

4BIO Capital | Activity | F4

trogenix.com

JUN 25, 2026

Investment

Led oversubscribed £61M ($83M) Series A for Cytospire Therapeutics, developing pan-gamma delta T cell engagers for solid tumors.

Cytospire Therapeutics

Cytospire Therapeutics 4BIO Capital

globenewswire.comMAY 5, 2026

MAY 5, 2026

Investment

Participated as existing investor in Ray Therapeutics' upsized and oversubscribed $125M Series B for optogenetic retinal disease therapies.

Ray Therapeutics

Ray Therapeutics 4BIO Capital

globenewswire.comAPR 21, 2026

APR 21, 2026

Team Change

Appointed Dr. Tetsu Maruyama, former Head of Drug Discovery at Takeda Pharmaceuticals, as Venture Partner based in Japan.

Tetsu Maruyama joined as Venture Partner

4BIO Capital

4biocapital.comMAR 30, 2026

MAR 30, 2026

Team Change

Promoted Dr. Therese Liechtenstein, previously Investment Director since 2024, to Partner.

Therese Liechtenstein promoted to Partner

4BIO Capital

4biocapital.comMAR 30, 2026

MAR 30, 2026

Investment

4BIO-founded Trogenix secured £70M ($95M) Series A led by IQ Capital to advance precision viral immunotherapy for glioblastoma.

Trogenix

Trogenix 4BIO Capital

globenewswire.comOCT 6, 2025

OCT 6, 2025

Investment

Co-led Actithera's oversubscribed $75.5M Series A for FAP-targeting radiopharmaceutical therapies.

Actithera

Actithera 4BIO Capital

globenewswire.comJUL 9, 2025

JUL 9, 2025

Exit

Portfolio company Araris Biotech agreed to be acquired by Taiho Pharmaceutical for up to $1.14B, a landmark exit for the firm.

Araris Biotech

Araris Biotech 4BIO Capital

globenewswire.comMAR 17, 2025

MAR 17, 2025

News

Became the first and only UK-based venture fund to achieve AMED certification, enabling portfolio companies to access Japanese non-dilutive government grants.

First UK VC Fund Certified by Japan's AMED

4BIO Capital

globenewswire.comNOV 14, 2024

NOV 14, 2024

Team Change

Appointed Dr. Therese Liechtenstein as Investment Director and Tay Salimullah as Venture Partner to strengthen the investment team.

Therese Liechtenstein and Tay Salimullah join team

4BIO Capital

globenewswire.comNOV 4, 2024

NOV 4, 2024

Investment

Led oversubscribed $28.4M Series A for March Biosciences, developing precision immune therapies for aggressive cancers.

March Biosciences

March Biosciences4BIO Capital

globenewswire.comOCT 23, 2024

OCT 23, 2024

Milestone

Portfolio company Ascend Advanced Therapies acquired Florida-based GMP manufacturing capacity from Beacon Therapeutics, expanding gene therapy production.

Ascend Advanced Therapies

Ascend Advanced Therapies4BIO Capital

globenewswire.comAPR 9, 2024

APR 9, 2024

New Fund

Development Bank of Japan invested in 4BIO Ventures III, targeting $200-300M for advanced therapies globally, with a Japan-focused strategy.

Ventures III Fund

4BIO Capital

globenewswire.comJAN 4, 2024

JAN 4, 2024